Effects of Rituximab on the Progression of Type 1 Diabetes in New Onset Subjects

This study has been completed.

Study NCT00279305 Information provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

First Received: January 17, 2006 Last Updated: January 5, 2009 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	December 2006
Estimated Primary Completion Date:	No date given

No publications provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009 Nov 26;361(22):2143-52.